MedTrace Logo

Oral vs. Intravenous TXA Study Proposal: TJA

NCT02233101 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2017-11-28

Study results available
· View outcomes & findings →

Summary

Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery.

Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.

Conditions

  • Blood Loss After Primary Total Joint Arthroplasty
  • Need for Blood Transfusion After Total Joint Arthroplasty

Interventions

DRUG

Oral Tranexamic Acid

patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement

DRUG

Intravenous Tranexamic Acid

Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Craig J Della Valle, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02233101 on ClinicalTrials.gov